Project Grant R03HL187208
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $241K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $761,573 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a pragmatic, open-label, randomized clinical trial comparing the effectiveness and safety of azithromycin versus doxycycline in combination with beta-lactam therapy for hospitalized adult patients with community-acquired pneumonia. The trial will enroll and randomize 1,120 adult patients hospitalized with community-acquired...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $242,100 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a translational precision-cut lung slice (PCLS) model for testing host-response mechanisms and therapeutic agents in Pneumocystis pneumonia. The project, titled "A Translational Precision-Cut Lung Slice Model for Host-Response and Therapeutic Testing in Pneumocystis Pneumonia,"...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $441,100 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research targeting phosphoglucomutase in Pneumocystis pneumonia. The research addresses the glucan-rich cell wall of Pneumocystis, which synthesizes β-glucans from uridine diphosphate glucose, a pathway requiring phosphoglucomutase (PGM) to interconvert glucose-6-phosphate and glucose-1-phosphate. Prior...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $1,665,204 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae. The research defines how severe respiratory infections such as influenza and SARS-CoV-2 promote pathogenic lung CD4+ T cell accumulation that perpetuates long-term lung damage, including the irreversible organ dysfunction observed in long COVID...
- Federal Project Grant Award Summary Mayo Clinic Arizona, a nonprofit academic medical center and research institution, received a $486,109 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award, effective July 1, 2025, through June 30, 2027, supports investigator-initiated biomedical research examining Type 2 immune responses in endotoxemia-induced lung injury. The research project...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- Federal Grant Award Summary Mayo Clinic received a $783,661 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion scheduled for August 31, 2026. The award funds a pragmatic, randomized clinical trial evaluating the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study seeks to reduce intensive...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $638,403 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the roles of group 2 innate lymphoid cells (ILC2s) in type 2 immunity and asthma. The project examines immunological mechanisms underlying airway inflammation in asthma patients, focusing on how ILC2s—which rapidly produce type 2 cytokines—regulate adaptive immune responses in the lungs and...
- The National Institute of Allergy and Infectious Diseases awarded Mainehealth a $489,848 Project Grant on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate combination therapy targeting methicillin-resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis patients. The research optimizes dosing and evaluates efficacy of ceftaroline-meropenem combination therapy in chronic MRSA infections, with and without CFTR modulators. The...